Product Name :
(-)-Narwedine
Description:
(-)-Narwedine is a cholinesterase (AChE) inhibitor for the treatment of mild to moderate Alzheimer’s disease.
CAS:
510-77-0
Molecular Weight:
285.34
Formula:
C17H19NO3
Chemical Name:
(4aS,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-one
Smiles :
COC1=CC=C2CN(C)CC[C@@]34C=CC(=O)C[C@@H]3OC1=C42
InChiKey:
QENVUHCAYXAROT-YOEHRIQHSA-N
InChi :
InChI=1S/C17H19NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,14H,7-10H2,1-2H3/t14-,17-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥360 days if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
(-)-Narwedine is a cholinesterase (AChE) inhibitor for the treatment of mild to moderate Alzheimer’s disease.|Product information|CAS Number: 510-77-0|Molecular Weight: 285.34|Formula: C17H19NO3|Synonym:|Galanthaminone|Narwedine|3-Deoxy-3-oxo-galanthamine|(-)-Narwedine|Chemical Name: (4aS,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-one|Smiles: COC1=CC=C2CN(C)CC[C@@]34C=CC(=O)C[C@@H]3OC1=C42|InChiKey: QENVUHCAYXAROT-YOEHRIQHSA-N|InChi: InChI=1S/C17H19NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,14H,7-10H2,1-2H3/t14-,17-/m0/s1|Technical Data|Appearance: Solid Power.|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.|HS Tariff Code: 382200|How to use|In Vitro:|(-)-Narwedine reduces the action of AChE and therefore tends to increase the concentration of acetylcholine in the brain.{{Nordihydroguaiaretic acid} MedChemExpress|{Nordihydroguaiaretic acid} Apoptosis|{Nordihydroguaiaretic acid} Protocol|{Nordihydroguaiaretic acid} Formula|{Nordihydroguaiaretic acid} custom synthesis|{Nordihydroguaiaretic acid} Autophagy} is also an allosteric ligand at nicotinic acetylcholine receptors.{{MSAB} MedChemExpress|{MSAB} Wnt|{MSAB} Epigenetics|{MSAB} Technical Information|{MSAB} Purity|{MSAB} custom synthesis} It has shown activity in modulating the nicotinic cholinergic receptors on cholinergic neurons to increase acetylcholine release.PMID:24670464 |In Vivo:|Absorption of (-)-Narwedine is rapid and complete and shows linear pharmacokinetics. It is well absorbed with absolute oral bioavailability between 80 and 100%. It has a half-life of seven hours. Peak effect of inhibiting acetylcholinesterase was achieved about one hour after a single oral dose of 8 mg in some healthy volunteers.|References:|Bickel U, Thomsen T, Weber W, Fischer JP, Bachus R, Nitz M, Kewitz H.Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther. 1991 Oct;50(4):420-8. PubMed PMID: 1914378.Thomsen T, Bickel U, Fischer JP, Kewitz H. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol.1990;39(6):603-5. PubMed PMID: 2095347.Mihailova D, Yamboliev I, Zhivkova Z, Tencheva J, Jovovich V. Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology. 1989;39(1):50-8. PubMed PMID: 2587617.Products are for research use only. Not for human use.|